417 related articles for article (PubMed ID: 9270089)
1. Inhibition of Na/K ATPase from rat aorta by two Na/K pump inhibitors, ouabain and marinobufagenin: evidence of interaction with different alpha-subunit isoforms.
Fedorova OV; Bagrov AY
Am J Hypertens; 1997 Aug; 10(8):929-35. PubMed ID: 9270089
[TBL] [Abstract][Full Text] [Related]
2. Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na+, K+-pump in human mesenteric arteries.
Bagrov AY; Fedorova OV
J Hypertens; 1998 Dec; 16(12 Pt 2):1953-8. PubMed ID: 9886882
[TBL] [Abstract][Full Text] [Related]
3. ANP differentially modulates marinobufagenin-induced sodium pump inhibition in kidney and aorta.
Fedorova OV; Agalakova NI; Morrell CH; Lakatta EG; Bagrov AY
Hypertension; 2006 Dec; 48(6):1160-8. PubMed ID: 17043158
[TBL] [Abstract][Full Text] [Related]
4. Effects of two endogenous Na+,K(+)-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta.
Bagrov AY; Roukoyatkina NI; Pinaev AG; Dmitrieva RI; Fedorova OV
Eur J Pharmacol; 1995 Feb; 274(1-3):151-8. PubMed ID: 7768267
[TBL] [Abstract][Full Text] [Related]
5. Phorbol diacetate potentiates na(+)-k(+) ATPase inhibition by a putative endogenous ligand, marinobufagenin.
Fedorova OV; Dorofeeva NA; Lopatin DA; Lakatta EG; Bagrov AY
Hypertension; 2002 Feb; 39(2):298-302. PubMed ID: 11847201
[TBL] [Abstract][Full Text] [Related]
6. Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats.
Fedorova OV; Kolodkin NI; Agalakova NI; Lakatta EG; Bagrov AY
Hypertension; 2001 Feb; 37(2 Pt 2):462-6. PubMed ID: 11230319
[TBL] [Abstract][Full Text] [Related]
7. Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism.
Bagrov AY; Dmitrieva RI; Dorofeeva NA; Fedorova OV; Lopatin DA; Lakatta EG; Droy-Lefaix MT
J Hypertens; 2000 Feb; 18(2):209-15. PubMed ID: 10694190
[TBL] [Abstract][Full Text] [Related]
8. [Role of the alpha2-isoform of Na+, K(+)-ATPase in the positive inotropic effect of ouabain and marinobufagenin in the rat diaphragm].
Krivoĭ II; Drabkina TM; Kravtsova VV; Vasil'ev AN; Vashchinkina EV; Prokof'ev AV; Kubasov IV
Biofizika; 2006; 51(5):906-11. PubMed ID: 17131832
[TBL] [Abstract][Full Text] [Related]
9. Plasma marinobufagenin-like and ouabain-like immunoreactivity in adrenocorticotropin-treated rats.
Fedorova OV; Anderson DE; Bagrov AY
Am J Hypertens; 1998 Jul; 11(7):796-802. PubMed ID: 9683040
[TBL] [Abstract][Full Text] [Related]
10. Selective ligands for Na
Chakraborty D; Fedorova OV; Bagrov AY; Kaphzan H
Neuropharmacology; 2017 May; 117():338-351. PubMed ID: 28232062
[TBL] [Abstract][Full Text] [Related]
11. Endogenous marinobufagenin-like immunoreactive substance. A possible endogenous Na, K-ATPase inhibitor with vasoconstrictor activity.
Bagrov AY; Dmitrieva RI; Fedorova OV; Kazakov GP; Roukoyatkina NI; Shpen VM
Am J Hypertens; 1996 Oct; 9(10 Pt 1):982-90. PubMed ID: 8896650
[TBL] [Abstract][Full Text] [Related]
12. Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor.
Fedorova OV; Zhuravin IA; Agalakova NI; Yamova LA; Talan MI; Lakatta EG; Bagrov AY
J Hypertens; 2007 Sep; 25(9):1834-44. PubMed ID: 17762648
[TBL] [Abstract][Full Text] [Related]
13. Binding of ouabain and marinobufagenin leads to different structural changes in Na,K-ATPase and depends on the enzyme conformation.
Klimanova EA; Petrushanko IY; Mitkevich VA; Anashkina AA; Orlov SN; Makarov AA; Lopina OD
FEBS Lett; 2015 Sep; 589(19 Pt B):2668-74. PubMed ID: 26297827
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the interaction between nicotinic acetylcholine receptor and Na+,K(+)-ATPase in the rat skeletal muscle and the Torpedo electric organ membrane preparation].
Krivoĭ II; Drabkina TM; Vasil'ev AN; Kravtsova VV; Mandel F
Ross Fiziol Zh Im I M Sechenova; 2006 Feb; 92(2):191-203. PubMed ID: 16739652
[TBL] [Abstract][Full Text] [Related]
15. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia.
Lopatin DA; Ailamazian EK; Dmitrieva RI; Shpen VM; Fedorova OV; Doris PA; Bagrov AY
J Hypertens; 1999 Aug; 17(8):1179-87. PubMed ID: 10466474
[TBL] [Abstract][Full Text] [Related]
16. Digitalis-like and vasoconstrictor effects of endogenous digoxin-like factor(s) from the venom of Bufo marinus toad.
Bagrov AY; Roukoyatkina NI; Fedorova OV; Pinaev AG; Ukhanova MV
Eur J Pharmacol; 1993 Apr; 234(2-3):165-72. PubMed ID: 8387009
[TBL] [Abstract][Full Text] [Related]
17. Reduced Na-K pump but increased Na-K-2Cl cotransporter in aorta of streptozotocin-induced diabetic rat.
Michea L; Irribarra V; Goecke IA; Marusic ET
Am J Physiol Heart Circ Physiol; 2001 Feb; 280(2):H851-8. PubMed ID: 11158986
[TBL] [Abstract][Full Text] [Related]
18. Effect of Na+ on Na+,K+-ATPase alpha-subunit expression and Na+-pump activity in aortic smooth muscle cells.
Liu X; Songu-Mize E
Eur J Pharmacol; 1998 Jun; 351(1):113-9. PubMed ID: 9698212
[TBL] [Abstract][Full Text] [Related]
19. Marinobufagenin enhances cardiac contractility in mice with ouabain-sensitive alpha1 Na+-K+-ATPase.
Wansapura AN; Lasko V; Xie Z; Fedorova OV; Bagrov AY; Lingrel JB; Lorenz JN
Am J Physiol Heart Circ Physiol; 2009 Jun; 296(6):H1833-9. PubMed ID: 19376809
[TBL] [Abstract][Full Text] [Related]
20. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs.
Bagrov AY; Fedorova OV; Dmitrieva RI; French AW; Anderson DE
Cardiovasc Res; 1996 Feb; 31(2):296-305. PubMed ID: 8730407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
